Results 171 to 180 of about 113,618,068 (200)
Some of the next articles are maybe not open access.
Gan to kagaku ryoho. Cancer & chemotherapy, 1987
CA 15-3 is a newly developed tumor marker detected by breast tumor-associated antigen 115D8/DF3 and is being studied as a monitoring marker in breast cancer patients (pts), even though its sensitivity as a screening marker is not so high. The cut off value of CA 15-3 was set at 27 U/ml.
M, Yoshimoto +8 more
openaire +1 more source
CA 15-3 is a newly developed tumor marker detected by breast tumor-associated antigen 115D8/DF3 and is being studied as a monitoring marker in breast cancer patients (pts), even though its sensitivity as a screening marker is not so high. The cut off value of CA 15-3 was set at 27 U/ml.
M, Yoshimoto +8 more
openaire +1 more source
Neoplasma, 1996
In the present study results of serum CA 15-3 immunoassay obtained at diagnosis in 231 breast cancer women (average age: 54.6, range: 27-87 years) were correlated with prognostic factors of the disease; the cut-off level was established at 30.0 U/ ml.
J, Wojtacki +5 more
openaire +1 more source
In the present study results of serum CA 15-3 immunoassay obtained at diagnosis in 231 breast cancer women (average age: 54.6, range: 27-87 years) were correlated with prognostic factors of the disease; the cut-off level was established at 30.0 U/ ml.
J, Wojtacki +5 more
openaire +1 more source
Anticancer research, 1997
Previously a higher preoperative sensitivity of the mucin like glycoprotein Mammary Serum Antigen (MSA) compared to established tumor markers was reported. The aim of our study was the comparison of MSA and CA 549, CA 15-3 and CEA in primary breast cancer and the correlation to prognostic factors.
T, Heinze +3 more
openaire +1 more source
Previously a higher preoperative sensitivity of the mucin like glycoprotein Mammary Serum Antigen (MSA) compared to established tumor markers was reported. The aim of our study was the comparison of MSA and CA 549, CA 15-3 and CEA in primary breast cancer and the correlation to prognostic factors.
T, Heinze +3 more
openaire +1 more source
Clinical Chemistry
Abstract Background Tumor marker (TM) testing plays an important role in monitoring chemotherapy response in metastatic breast cancer. While the American Society of Clinical Oncology (ASCO) guidelines consider CA 15-3 and CA 27.29 clinically equivalent, they differ analytically due to distinct ...
Usman Sunusi +7 more
openaire +1 more source
Abstract Background Tumor marker (TM) testing plays an important role in monitoring chemotherapy response in metastatic breast cancer. While the American Society of Clinical Oncology (ASCO) guidelines consider CA 15-3 and CA 27.29 clinically equivalent, they differ analytically due to distinct ...
Usman Sunusi +7 more
openaire +1 more source
Critical care management of chimeric antigen receptor T-cell therapy recipients
Ca-A Cancer Journal for Clinicians, 2022Sandrine Valadè +2 more
exaly
Comparison of CA 15-3 and carcino-embryonic antigen levels in women with breast cancer
Journal of Steroid Biochemistry, 1987F. May-Levin +3 more
openaire +1 more source
A review of cancer immunotherapy toxicity
Ca-A Cancer Journal for Clinicians, 2020Lucy Boyce Kennedy
exaly